MA26855A1 - Activateurs de glucokinases transolefiniques - Google Patents

Activateurs de glucokinases transolefiniques

Info

Publication number
MA26855A1
MA26855A1 MA26690A MA26690A MA26855A1 MA 26855 A1 MA26855 A1 MA 26855A1 MA 26690 A MA26690 A MA 26690A MA 26690 A MA26690 A MA 26690A MA 26855 A1 MA26855 A1 MA 26855A1
Authority
MA
Morocco
Prior art keywords
transolefinic
glucokinases
activators
transolefinic glucokinases
Prior art date
Application number
MA26690A
Other languages
English (en)
Inventor
Ramakanth Sarabu
Achyutharao Sidduri
Wendy Lea Corbett
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26855A1 publication Critical patent/MA26855A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA26690A 1999-12-15 2002-06-14 Activateurs de glucokinases transolefiniques MA26855A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17078399P 1999-12-15 1999-12-15

Publications (1)

Publication Number Publication Date
MA26855A1 true MA26855A1 (fr) 2004-12-20

Family

ID=22621235

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26690A MA26855A1 (fr) 1999-12-15 2002-06-14 Activateurs de glucokinases transolefiniques

Country Status (33)

Country Link
US (1) US6353111B1 (fr)
EP (1) EP1242397B1 (fr)
JP (1) JP3824936B2 (fr)
KR (1) KR100502032B1 (fr)
CN (1) CN1185219C (fr)
AR (1) AR032752A1 (fr)
AT (1) ATE305461T1 (fr)
AU (1) AU781029B2 (fr)
CA (1) CA2392903C (fr)
CO (1) CO5050295A1 (fr)
CZ (1) CZ20022412A3 (fr)
DE (1) DE60022903T2 (fr)
DK (1) DK1242397T3 (fr)
ES (1) ES2249322T3 (fr)
GC (1) GC0000264A (fr)
HK (1) HK1054383B (fr)
HR (1) HRP20020514A2 (fr)
HU (1) HUP0203753A3 (fr)
IL (2) IL150083A0 (fr)
JO (1) JO2180B1 (fr)
MA (1) MA26855A1 (fr)
MX (1) MXPA02005874A (fr)
MY (1) MY125484A (fr)
NO (1) NO323142B1 (fr)
NZ (1) NZ518974A (fr)
PE (1) PE20011022A1 (fr)
PL (1) PL355815A1 (fr)
RU (1) RU2245332C2 (fr)
TW (1) TWI262916B (fr)
UY (1) UY26483A1 (fr)
WO (1) WO2001044216A1 (fr)
YU (1) YU41402A (fr)
ZA (1) ZA200203829B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
US7410956B2 (en) 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
EP1496052B1 (fr) 2002-03-26 2009-08-05 Banyu Pharmaceutical Co., Ltd. Nouveau derive aminobenzamide
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
BR0314864A (pt) * 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7262196B2 (en) * 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
BRPI0507746A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
BRPI0509573A (pt) * 2004-04-02 2007-09-25 Novartis Ag derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
US7781451B2 (en) * 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
UA90264C2 (ru) * 2004-04-21 2010-04-26 Прозидион Лтд. Три(цикло)замещенные амиды, фармацевтическая композиция, способы лечения и профилактики, способ получения соединения
MXPA06012008A (es) * 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
US20080026987A1 (en) * 2004-06-17 2008-01-31 Novo Nordisk A/S Use of Liver-Selective Glucokinase Activators
KR100890695B1 (ko) * 2004-08-12 2009-03-26 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의그의 용도
JP2009500377A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
KR101346902B1 (ko) 2005-07-09 2014-01-02 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체
EP1910317B1 (fr) 2005-07-20 2013-07-03 Eli Lilly And Company Composés joints en position 1-amino
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (fr) 2005-09-29 2007-04-12 Sanofi-Aventis Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
WO2007051845A1 (fr) * 2005-11-03 2007-05-10 Prosidion Ltd Amides a substitution tricyclo
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
EP1948614A2 (fr) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Activateurs de la glucokinase
EP2001875A2 (fr) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Activateurs de la glucokinase
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2049518B1 (fr) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Derives de l'indazole et de l'isoindazole comme agents de l'activation de glucokinase
ES2581765T3 (es) 2006-08-24 2016-09-07 University Of Tennessee Research Foundation Acilanilidas sustituidas y métodos de uso de las mismas
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
US7902248B2 (en) * 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
CA2679185A1 (fr) 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited Derives d'acetamide 2,2,2-tri-substitue en tant qu'activateurs de la glucokinase, leur procede de preparation et leur application pharmaceutique
JP5248477B2 (ja) * 2007-03-07 2013-07-31 杏林製薬株式会社 グルコキナーゼ活性化物質
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
EP2203448B1 (fr) * 2007-09-21 2011-06-22 Sanofi-Aventis Dérivés de phénothiazine à liaison double, procédé pour les produire et leur utilisation comme médicaments
TW200934772A (en) * 2008-01-15 2009-08-16 Lilly Co Eli Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
JP5287730B2 (ja) 2008-01-18 2013-09-11 アステラス製薬株式会社 フェニルアセトアミド誘導体
KR101608259B1 (ko) * 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체
KR20110018366A (ko) 2008-05-16 2011-02-23 다케다 샌디에고, 인코포레이티드 글루코키나아제 활성제
US8450494B2 (en) 2009-06-22 2013-05-28 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (GK) activators
UA103807C2 (ru) 2009-07-31 2013-11-25 Кадила Хелткере Лимитед Замещенные бензамидные производные как активаторы глюкокиназы (gk)
KR100970871B1 (ko) * 2009-11-30 2010-07-20 케이제이알디 (주) 바닥재 어셈블리 및 바닥재의 시공방법
AU2010327597B2 (en) 2009-12-04 2014-06-19 Nissan Chemical Industries, Ltd. 2-Pyridone compounds
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
LT2872482T (lt) 2012-07-13 2020-12-28 Oncternal Therapeutics, Inc. Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
DK2921489T3 (en) 2012-11-13 2017-10-16 Nissan Chemical Ind Ltd 2-pyridone-RELATED
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3181722A1 (fr) 2020-06-08 2021-12-16 Jing TENG Sels ou co-cristaux de {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acide acetique et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5169951A (en) 1990-04-23 1992-12-08 Ciba-Geigy Corporation Process for preparing nematicidal compositions
US5510478A (en) * 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
PL350669A1 (en) * 1999-03-29 2003-01-27 Hoffmann La Roche Glucokinase activators

Also Published As

Publication number Publication date
DE60022903D1 (de) 2006-02-09
PL355815A1 (en) 2004-05-17
CZ20022412A3 (cs) 2002-10-16
CN1185219C (zh) 2005-01-19
HK1054383B (zh) 2005-04-22
JO2180B1 (en) 2003-04-23
ES2249322T3 (es) 2006-04-01
TWI262916B (en) 2006-10-01
NZ518974A (en) 2004-04-30
AU2365201A (en) 2001-06-25
NO323142B1 (no) 2007-01-08
ZA200203829B (en) 2003-08-14
DK1242397T3 (da) 2006-02-13
CN1411453A (zh) 2003-04-16
RU2245332C2 (ru) 2005-01-27
EP1242397B1 (fr) 2005-09-28
CO5050295A1 (es) 2001-06-27
WO2001044216A1 (fr) 2001-06-21
US6353111B1 (en) 2002-03-05
AR032752A1 (es) 2003-11-26
NO20022863L (no) 2002-06-14
AU781029B2 (en) 2005-04-28
CA2392903A1 (fr) 2001-06-21
HUP0203753A3 (en) 2004-12-28
CA2392903C (fr) 2008-08-05
GC0000264A (en) 2006-11-01
DE60022903T2 (de) 2006-07-06
IL150083A (en) 2010-04-15
HK1054383A1 (en) 2003-11-28
JP3824936B2 (ja) 2006-09-20
NO20022863D0 (no) 2002-06-14
UY26483A1 (es) 2001-06-29
HUP0203753A2 (hu) 2003-03-28
EP1242397A1 (fr) 2002-09-25
KR20020067555A (ko) 2002-08-22
JP2003516980A (ja) 2003-05-20
MY125484A (en) 2006-08-30
HRP20020514A2 (en) 2004-06-30
PE20011022A1 (es) 2001-10-11
MXPA02005874A (es) 2002-10-23
IL150083A0 (en) 2002-12-01
YU41402A (sh) 2005-07-19
KR100502032B1 (ko) 2005-07-25
ATE305461T1 (de) 2005-10-15

Similar Documents

Publication Publication Date Title
MA26855A1 (fr) Activateurs de glucokinases transolefiniques
PT1169312E (pt) Activadores de glicocinase
FI973816A0 (fi) Polypropen med hoeg smaeltstyrka
ID30262A (id) Ligan reseptor melanokortin
PT1210113E (pt) Composicoes de vacinas de combinacao
NO2012005I1 (no) Romiplostim
DK1218382T3 (da) Bicykliske imidazo-3-ylaminderivater
ID30233A (id) Antibiotika ketolida
NO20004971L (no) Forlengingsrørhenger
IS2277B (is) Meðferðarlegar bíarýl afleiður
ID24458A (id) Modifikasi rheologi in-sito poliolefin
DE50015443D1 (de) Bicyclische imidazo-5-yl-aminderivate
PT1246817E (pt) Derivados de 4-fenil-1-piperazinilo, -piperidinilo e -tetra-hidropiridilo
PT1022396E (pt) Combinacao de duche
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
ID30023A (id) Kombinasi senyawa aktif fungisida
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
EE200100381A (et) Morfolinobensamiidi uued soolad
PT1175417E (pt) Compostos substituidos de benzolactamas
ID30381A (id) Penggunaan arilalkanoilpiridazina
PT1232141E (pt) Eteres de o-desmetil-venlafaxina
FI974544A0 (fi) Anordning i en med manoeverplats foersedd lastkran
EP1219303A4 (fr) Promoteurs de chondrogenese
FI982552A0 (fi) Stabilointimenetelmä
BR1100811A (pt) Derivados de 1-metil-carbapenema